

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



32567-H

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C07K 14/47, C12N 15/12, C12Q 1/68, C12N 15/10, C07K 16/18, G01N 33/53, A61K 38/17, A61P 13/12		A2	(11) International Publication Number: WO 00/61622 (43) International Publication Date: 19 October 2000 (19.10.00)
(21) International Application Number: PCT/US00/08260 (22) International Filing Date: 28 March 2000 (28.03.00) (30) Priority Data: 09/289,349 9 April 1999 (09.04.99) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application 09/289,349 (CIP) US Filed on 9 April 1999 (09.04.99) (71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3160 Porter Drive, Palo Alto, CA 94304 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): WALKER, Michael, G. [CA/US]; Unit 80, 1050 Borregas Avenue, Sunnyvale, CA 94089 (US). VOLKMUTH, Wayne [US/US]; Apt. 613, 5916 North Las Virgenes Road, Calabasas, CA 91302 (US). KLINGLER, Tod, M. [US/US]; 28 Dover Court, San Carlos, CA 94070 (US). AZIMZAI, Yalda [US/US]; 2045 Rock		Springs Drive, Hayward, CA 94545 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). (74) Agents: MURRY, Lynn, E. et al.; Incyte Pharmaceuticals, Inc., 3160 Porter Drive, Palo Alto, CA 94304 (US). (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW); Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM); European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published Without international search report and to be republished upon receipt of that report.	
(54) Title: GENES ASSOCIATED WITH DISEASES OF THE KIDNEY			
(57) Abstract The invention provides novel kidney disease-associated genes and polypeptides encoded by those genes. The invention also provides expression vectors, host cells, and antibodies. The invention further provides methods for diagnosing, treating or preventing diseases of the kidney.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

GENES ASSOCIATED WITH DISEASES OF THE KIDNEY

TECHNICAL FIELD

The invention relates to nine genes associated with diseases of the kidney, as identified by
5 their coexpression with genes known to be associated with renal disorders. The invention also
relates to polypeptides encoded by these genes and to the use of these amino acid and nucleic acid
sequences in the diagnosis, prognosis, prevention, treatment, and evaluation of therapies for diseases
of the kidney.

BACKGROUND ART

10 The kidneys excrete waste and contribute to maintenance of homeostasis by regulating
blood pH electrolyte levels and blood pressure. Renal failure or dysfunction is the cause of several
diseases whose clinical manifestations are typically hyper- or hypo-tension. These diseases include
Bartter's syndrome, Gitelman syndrome, autosomal dominant polycystic kidney disease, and
nephrolithiasis.

15 Treatment with antibiotics such as gentamycin, tobramycin, or amikacin can lead to tubular
necrosis with consequent risk of acute renal failure in as much as 25% of patients. A cumulative
dose of 2 to 3 grams amphotericin B is likewise nephrotoxic. Cyclosporine, an immunosuppressant
given to organ transplant patients, is also nephrotoxic. The molecular basis for the nephrotoxicity
of these and other compounds is not understood, although calbindin D levels appear to be a useful
20 diagnostic marker signaling cyclosporine-induced nephrotoxicity (Aicher *et al.* (1998)
Electrophoresis 19:1998-2003). Similarly, reductions in urinary excretion of proteins such as
Tamm-Horsfall protein, beta 2 microglobulin, and urinary retinol binding protein, appear to be
diagnostic for nephrotoxicity when induced by certain chemotherapeutic agents including ifosfamide
and cisplatin (MacLean *et al.* (1998) *Cancer Chemother. Pharmacol.* 41:413-416; Tokuc *et al.*
25 (1997) *J. Exp. Clin. Cancer Res.* 16:227-230).

We have identified nine novel kidney disease-associated genes through their co-expression
with genes known to affect kidney function in normal and diseased states. The present invention
satisfies a need in the art by providing new amino acid and nucleic acid compositions that are useful
for diagnosis, prognosis, treatment, prevention, and evaluation of therapies for renal disorders.

30

SUMMARY OF THE INVENTION

In one aspect, the invention provides for a substantially purified polynucleotide comprising
a gene, that is coexpressed with one or more known kidney disease-associated genes in a plurality of
biological samples. Preferably, known kidney disease-associated genes are selected from the group
consisting of uromodulin, NKCC2 (bumetanide-sensitive Na-K-C1 cotransporter 2), NCCT

(thiazine-sensitive Na-Cl cotransporter), aldolase B, ROMK1 (inwardly-rectifying voltage-gated K channel), ATP1G1 (Na-K ATPase gamma subunit), PDZK 1 (PDZ domain-containing protein), NPT-1 (Na-dependent phosphate cotransporter), calbindin, kininogen, and CIC-Kb (chloride channel). Preferred embodiments include (a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:9 (SEQ ID NOs:1-9); (b) a polynucleotide sequence which encodes a polypeptide sequence selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12 (SEQ ID NOs:10-12); (c) a polynucleotide sequence having at least 75% identity to the polynucleotide sequence of (a) or (b); (d) a polynucleotide sequence which is complementary to the polynucleotide sequence of (a), (b), or (c); (e) a polynucleotide sequence comprising at least 10, preferably at least 18, sequential nucleotides of the polynucleotide sequence of (a), (b), (c), or (d); or (f) a polynucleotide which hybridizes under stringent conditions to the polynucleotide of (a), (b), (c), (d), or (e). Furthermore, the invention provides an expression vector comprising any of the above described polynucleotides, and a host cell containing the expression vector. Still further, the invention provides a method for treating or preventing a disease or condition associated with the altered expression of a gene that is coexpressed one or more known kidney disease-associated genes comprising administering to a subject in need a polynucleotide described above in an amount effective for treating or preventing the disease.

In a second aspect, the invention provides a substantially purified polypeptide comprising the gene product of a gene that is coexpressed with one or more known kidney disease-associated genes in a plurality of biological samples. The known kidney disease-associated gene may be selected from the group consisting of uromodulin, NKCC2, NCCT, aldolase B, ROMK1, ATP1G1, PDZK1, NPT-1, calbindin, kininogen, and CIC-Kb. Preferred embodiments are (a) the polypeptide sequence selected from the group consisting of SEQ ID NOs:10-12; (b) a polypeptide sequence having at least 85% identity to the polypeptide sequence of (a); and (c) a polypeptide sequence comprising at least 6 sequential amino acids of the polypeptide sequence of (a) or (b). Additionally, the invention provides antibodies that bind specifically to any of the above described polypeptides and a method for treating or preventing a disease or condition associated with the altered expression of a gene that is coexpressed with one or more known kidney disease-associated genes comprising administering to a subject in need such an antibody in an amount effective for treating or preventing the disease.

In another aspect, the invention provides a pharmaceutical composition comprising the polynucleotide of claim 2 or the polypeptide of claim 3 in conjunction with a suitable pharmaceutical carrier and a method for treating or preventing a disease or condition associated

with the altered expression of a gene that is coexpressed with one or more known kidney disease-associated genes comprising administering to a subject in need such a composition in an amount effective for treating or preventing the disease.

In a further aspect, the invention provides a method for diagnosing a disease or condition associated with the altered expression of a gene that is coexpressed with one or more known kidney disease-associated genes, wherein each known kidney disease-associated gene is selected from the group consisting of uromodulin, NKCC2, NCCT, aldolase 13, ROMK1, ATP1G1, PDZK1, NPT-1, calbindin, kininogen, and CIC-Kb. The method comprises the steps of (a) providing a sample comprising one or more of the coexpressed genes; (b) hybridizing the polynucleotide of claim 2 to the coexpressed genes under conditions effective to form one or more hybridization complexes; (c) detecting the hybridization complexes; and (d) comparing the levels of the hybridization complexes with the level of hybridization complexes in a nondiseased sample, wherein altered levels of one or more of the hybridization complexes in a diseased sample compared with the level of hybridization complexes in a non-diseased sample correlates with the presence of the disease or condition.

Additionally, the invention provides antibodies, antibody fragments, and immunoconjugates that exhibit specificity to any of the above described polypeptides and methods for treating or preventing diseases or conditions of the kidney.

BRIEF DESCRIPTION OF THE SEQUENCE LISTING

The Sequence Listing provides exemplary kidney disease-associated gene sequences including polynucleotide sequences, SEQ ID NOs:1-9, and the polypeptide sequences, SEQ ID NOs:10-12. Each sequence is identified by a sequence identification number (SEQ ID NO) and by the Incyte clone number with which the sequence was first identified.

DESCRIPTION OF THE INVENTION

It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include the plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

DEFINITIONS

"NSEQ" refers generally to a polynucleotide sequence of the present invention, including SEQ ID NOs:1-9. "PSEQ" refers generally to a polypeptide sequence of the present invention, SEQ ID NOs:10-12.

A "fragment" refers to a nucleic acid sequence that is preferably at least 20 nucleic acids in

length, more preferably 40 nucleic acids, and most preferably 60 nucleic acids in length, and encompasses, for example, fragments consisting of nucleic acids 1-50, 51-400, 401-4000, 4001-12,000, and the like, of SEQ ID NOs:1-9.

"Gene" refers to the partial or complete coding sequence of a gene and to its 5' or 3' untranslated regions. The gene may be in a sense or antisense (complementary) orientation.

"Kidney disease-associated gene" refers to a gene whose expression pattern is similar to that of known kidney disease-associated genes which are useful in the diagnosis, treatment, prognosis, or prevention of diseases of the kidney. "Known kidney disease-associated gene" refers to a sequence which has been previously identified as useful in the diagnosis, treatment, prognosis, or prevention of diseases of the kidney. Typically, this means that the known gene is expressed at higher levels (i.e., has more abundant transcripts) in diseased or cancerous kidney tissue than in normal or non-diseased kidney or in any other tissue.

"Polynucleotide" refers to a nucleic acid, nucleic acid sequence, oligonucleotide, nucleotide, or any fragment thereof. It may be DNA or RNA of genomic or synthetic origin, double-stranded or single-stranded, and combined with carbohydrate, lipids, protein or other materials to perform a particular activity or form a useful composition. "Oligonucleotide" is substantially equivalent to the terms amplicon, primer, oligomer, element, and probe.

"Polypeptide" refers to an amino acid, amino acid sequence, oligopeptide, peptide, or protein or portions thereof whether naturally occurring or synthetic.

A "portion" refers to peptide sequence which is preferably at least 5 to about 15 amino acids in length, most preferably at least 10 amino acids long, and which retains some biological or immunological activity of, for example, a portion of SEQ ID NOs:10-12.

"Sample" is used in its broadest sense. A sample containing nucleic acids may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; genomic DNA, RNA, or cDNA in solution or bound to a substrate; a cell; a tissue; a tissue print; and the like.

"Substantially purified" refers to a nucleic acid or an amino acid sequence that is removed from its natural environment and that is isolated or separated, and is at least about 60% free, preferably about 75% free, and most preferably about 90% free, from other components with which it is naturally present.

"Substrate" refers to any suitable rigid or semi-rigid support to which polynucleotides or polypeptides are bound and includes membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, capillaries or other tubing, plates, polymers, and microparticles with a variety of surface forms including wells, trenches, pins, channels and pores.

A "variant" refers to a polynucleotide or polypeptide whose sequence diverges from SEQ ID NOs: 1-9. Polynucleotide sequence divergence may result from mutational changes such as deletions, additions, and substitutions of one or more nucleotides; it may also be introduced to accommodate differences in codon usage. Each of these types of changes may occur alone, or in combination, one or more times in a given sequence.

THE INVENTION

The present invention encompasses a method for identifying biomolecules that are associated with a specific disease, regulatory pathway, subcellular compartment, cell type, tissue type, or species. In particular, the method identifies genes useful in diagnosis, prognosis, treatment, prevention, and evaluation of therapies for diseases of the kidney including, but not limited, Bartter's syndrome, Gitelman syndrome, nephrolithiasis, renal amyloidosis, hypertension; primary aldosteronism; Addison's disease; renal failure; glomerulonephritis; chronic glomerulonephritis; tubulointerstitial nephritis; cystic disorders of the kidney and dysplastic malformations such as polycystic disease, renal dysplasias, and cortical or medullary cysts; inherited polycystic renal diseases (PRD), such as recessive and autosomal dominant PRD; medullary cystic disease; medullary sponge kidney and tubular dysplasia; Alport's syndrome; non-renal cancers which affect renal physiology, such as bronchogenic tumors of the lungs or tumors of the basal region of the brain; multiple myeloma; adenocarcinomas of the kidney; metastatic renal carcinoma; in addition, nephrotoxic disorders include any functional or morphologic change in the kidney produced by any pharmaceutical, chemical, or biological agent that is ingested, injected, inhaled, or absorbed. Some broad categories of common nephrotoxic agents are heavy metals, all classes of antibiotics, analgesics, solvents, oxalosis-inducing agents, anticancer drugs, herbicides and pesticides, botanicals and biologicals, and antiepileptics.

The method entails first identifying polynucleotides that are expressed in a plurality of cDNA libraries. The identified polynucleotides include genes of known or unknown function which are expressed in a specific disease process, subcellular compartment, cell type, tissue type, or species. The expression patterns of the genes with known function are compared with those of genes with unknown function to determine whether a specified coexpression probability threshold is met. Through this comparison, a subset of the polynucleotides having a high coexpression probability with the known genes can be identified. The high coexpression probability correlates with a particular coexpression probability threshold which is preferably less than 0.001 and more preferably less than 0.00001.

The polynucleotides originate from cDNA libraries derived from a variety of sources including, but not limited to, eukaryotes such as human, mouse, rat, dog, monkey, plant, and yeast;

prokaryotes such as bacteria; and viruses. These polynucleotides can also be selected from a variety of sequence types including, but not limited to, expressed sequence tags (ESTs), assembled polynucleotide sequences, full length gene coding regions, promoters, introns, enhancers, 5' untranslated regions, and 3' untranslated regions. To have statistically significant analytical results, 5 the polynucleotides need to be expressed in at least three cDNA libraries.

The cDNA libraries used in the coexpression analysis of the present invention can be obtained from adrenal gland, biliary tract, bladder, blood cells, blood vessels, bone marrow, brain, bronchus, cartilage, chromaffin system, colon, connective tissue, cultured cells, embryonic stem cells, endocrine glands, epithelium, esophagus, fetus, ganglia, heart, hypothalamus, immune system, 10 intestine, islets of Langerhans, kidney, larynx, liver, lung, lymph, muscles, neurons, ovary, pancreas, penis, peripheral nervous system, phagocytes, pituitary, placenta, pleurus, prostate, salivary glands, seminal vesicles, skeleton, spleen, stomach, testis, thymus, tongue, ureter, uterus, and the like. The number of cDNA libraries selected can range from as few as 3 to greater than 10,000. Preferably, the number of the 15 cDNA libraries is greater than 500.

In a preferred embodiment, genes are assembled from related sequences, such as assembled sequence fragments derived from a single transcript. Assembly of the polynucleotide sequences can be performed using sequences of various types including, but not limited to, ESTs, extensions, or shotgun sequences. In a most preferred embodiment, the polynucleotide sequences are derived from 20 human sequences that have been assembled using the algorithm disclosed in "Database and System for Storing, Comparing and Displaying Related Biomolecular Sequence Information", Lincoln *et al.* USSN 09/276,534, filed March 25, 1999, incorporated herein by reference.

Experimentally, differential expression of the polynucleotides can be evaluated by methods including, but not limited to, differential display by spatial immobilization or by gel electrophoresis, 25 genome mismatch scanning, representational difference analysis, and transcript imaging. Additionally, differential expression can be assessed by microarray technology. These methods may be used alone or in combination.

Known kidney disease-associated genes can be selected based on the use of these genes as diagnostic or prognostic markers or as therapeutic targets. Preferably, the known kidney disease-associated genes include uromodulin, NKCC2, NCCT, aldolase B, ROMK1, ATP1G1, PDZK1, 30 NPT-1, calbindin, kininogen, and CIC-Kb, and the like.

The procedure for identifying novel genes that exhibit a statistically significant coexpression pattern with known kidney disease-associated genes is as follows. First, the presence or absence of a gene in a cDNA library is defined: a gene is present in a cDNA library when at least one cDNA

fragment corresponding to that gene is detected in a cDNA sample taken from the library, and a gene is absent from a library when no corresponding cDNA fragment is detected in the sample.

Second, the significance of gene coexpression is evaluated using a probability method to measure a due-to-chance probability of the coexpression. The probability method can be the Fisher exact test, the chi-squared test, or the kappa test. These tests and examples of their applications are well known in the art and can be found in standard statistics texts (Agresti (1990) Categorical Data Analysis, John Wiley & Sons, New York NY; Rice (1988) Mathematical Statistics and Data Analysis, Duxbury Press, Pacific Grove CA). A Bonferroni correction (Rice, supra, p. 384) can also be applied in combination with one of the probability methods for correcting statistical results of one gene versus multiple other genes. In a preferred embodiment, the due-to-chance probability is measured by a Fisher exact test, and the threshold of the due-to-chance probability is set preferably to less than 0.001, more preferably to less than 0.00001.

To determine whether two genes, A and B, have similar coexpression patterns, occurrence data vectors can be generated as illustrated in Table 1. The presence of a gene occurring at least once in a library is indicated by a one, and its absence from the library, by a zero.

Table 1. Occurrence data for genes A and B

	Library 1	Library 2	Library 3	...	Library N
gene A	1	1	0	...	0
gene B	1	0	1	...	0

For a given pair of genes, the occurrence data in Table 1 can be summarized in a 2 x 2 contingency table.

Table 2. Contingency table for co-occurrences of genes A and B

	Gene A present	Gene A absent	Total
Gene B present	8	2	10
Gene B absent	2	18	20
Total	10	20	30

Table 2 presents co-occurrence data for gene A and gene B in a total of 30 libraries. Both gene A and gene B occur 10 times in the libraries. Table 2 summarizes and presents: 1) the number of times gene A and B are both present in a library; 2) the number of times gene A and B are both absent in a library; 3) the number of times gene A is present, and gene B is absent; and 4) the number of times gene B is present, and gene A is absent. The upper left entry is the number of

times the two genes co-occur in a library, and the middle right entry is the number of times neither gene occurs in a library. The off diagonal entries are the number of times one gene occurs, and the other does not. Both A and B are present eight times and absent 18 times. Gene A is present, and gene B is absent, two times; and gene B is present, and gene A is absent, two times. The probability ("p-value") that the above association occurs due to chance as calculated using a Fisher exact test is 0.0003. Associations are generally considered significant if a p-value is less than 0.01 (Agresti, supra; Rice, supra).

This method of estimating the probability for coexpression of two genes makes several assumptions. The method assumes that the libraries are independent and are identically sampled. However, in practical situations, the selected cDNA libraries are not entirely independent, because more than one library may be obtained from a single subject or tissue. Nor are they entirely identically sampled, because different numbers of cDNAs may be sequenced from each library. The number of cDNAs sequenced typically ranges from 5,000 to 10,000 cDNAs per library. In addition, because a Fisher exact coexpression probability is calculated for each gene versus 41,419 other assembled genes, a Bonferroni correction for multiple statistical tests is necessary.

Using the method of the present invention, we have identified nine novel genes that exhibit strong association, or coexpression, with known genes that are specific to kidney disease. These known kidney disease-associated genes include uromodulin, NKCC2, NCCT, aldolase B, ROMK1, ATP1G1, PDZK1, NPT-1, calbindin, kininogen, and CIC-Kb. The results presented in Table 4 show that the expression of the nine novel genes have direct or indirect association with the expression of known kidney disease-associated genes. Therefore, the novel genes can potentially be used in diagnosis, treatment, prognosis, or prevention of diseases of the kidney or in the evaluation of therapies for diseases of the kidney. Further, the gene products of the nine novel genes are either potential therapeutic proteins or targets of therapeutics against diseases of the kidney.

Therefore, in one embodiment, the present invention encompasses a polynucleotide sequence comprising the sequence of SEQ ID Nos:1-9. These nine polynucleotides are shown by the method of the present invention to have strong coexpression association with known kidney disease-associated genes and with each other. The invention also encompasses a variant of the polynucleotide sequence, its complement, or 18 consecutive nucleotides of a sequence provided in the above described sequences. Variant polynucleotide sequences typically have at least about 75%, more preferably at least about 85%, and most preferably at least about 95% polynucleotide sequence identity to NSEQ.

NSEQ or the encoded PSEQ may be used to search against the GenBank primate (pri), rodent (rod), mammalian (mam), vertebrate (vrtp), and eukaryote (eukp) databases, SwissProt,

BLOCKS (Bairoch *et al.* (1997) *Nucleic Acids Res.* 25:217-221), PFAM, and other databases that contain previously identified and annotated motifs, sequences, and gene functions. Methods that search for primary sequence patterns with secondary structure gap penalties (Smith *et al.* (1992) *Protein Engineering* 5:35-51) as well as algorithms such as Basic Local Alignment Search Tool (BLAST; Altschul (1993) *J. Mol. Evol.* 36:290-300; Altschul *et al.* (1990) *J. Mol. Biol.* 215:403-410), BLOCKS (Henikoff and Henikoff (1991) *Nucleic Acids Res.* 19:6565-6572), Hidden Markov Models (HMM; Eddy (1996) *Cur. Opin. Str. Biol.* 6:361-365; Sonnhammer *et al.* (1997) *Proteins* 28:405-420), and the like, can be used to manipulate and analyze nucleotide and amino acid sequences. These databases, algorithms and other methods are well known in the art and are described in Ausubel *et al.* (1997; Short Protocols in Molecular Biology, John Wiley & Sons, New York NY, unit 7.7) and Meyers (1995; Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853).

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to SEQ ID NOs:1-9, and fragments thereof under stringent conditions. Stringent conditions can be defined by salt concentration, temperature, and other chemicals and conditions well known in the art. Suitable conditions can be selected, for example, by varying the concentrations of salt in the prehybridization, hybridization, and wash solutions or by varying the hybridization and wash temperatures. With some substrates, the temperature can be decreased by adding formamide to the prehybridization and hybridization solutions.

Hybridization can be performed at low stringency, with buffers such as 5xSSC with 1% sodium dodecyl sulfate (SDS) at 60°C, which permits complex formation between two nucleic acid sequences that contain some mismatches. Subsequent washes are performed at higher stringency with buffers such as 0.2xSSC with 0.1% SDS at either 45°C (medium stringency) or 68°C (high stringency), to maintain hybridization of only those complexes that contain completely complementary sequences. Background signals can be reduced by the use of detergents such as SDS, Sarcosyl, or Triton X-100, and/or a blocking agent, such as salmon sperm DNA. Hybridization methods are described in detail in Ausubel (*supra*, units 2.8-2.11, 3.18-3.19 and 4.6-4.9) and Sambrook *et al.* (1989; Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY).

NSEQ can be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences such as promoters and other regulatory elements. (See, e.g., Dieffenbach and Dveksler (1995) *PCR Primer*, a Laboratory Manual, Cold Spring Harbor Press, Plainview NY.) Additionally, one may use an XL-PCR kit (PE Biosystems, Foster City, CA), nested primers, and commercially available cDNA libraries (Life

Technologies, Rockville MD) or genomic libraries (Clontech, Palo Alto CA) to extend the sequence. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 Primer Analysis software (National Biosciences, Plymouth MN) or another appropriate program, to be about 18 to 30 nucleotides in length, to have a GC content of about 50%, and to form a hybridization complex at temperatures of about 68°C to 72°C.

In another aspect of the invention, NSEQ can be cloned in recombinant DNA molecules that direct the expression of PSEQ, or structural or functional portions thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express the polypeptide encoded by NSEQ. The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter the nucleotide sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

In order to express a biologically active protein, NSEQ, or derivatives thereof, may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a particular host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions. Methods which are well known to those skilled in the art may be used construct such expression vectors. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, supra; and Ausubel, supra.)

A variety of expression vector/host cell systems may be utilized to express NSEQ. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with baculovirus vectors; plant cell systems transformed with viral or bacterial expression vectors; or animal cell systems. For long term production of recombinant proteins in mammalian systems, stable expression in cell lines is preferred. For example, NSEQ can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable or visible marker gene on the same or on a separate vector. The invention is not to be limited by the

vector or host cell employed.

In general, host cells that contain NSEQ and that express PSEQ may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences. Immunological methods for detecting and measuring the expression of PSEQ using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS).

Host cells transformed with NSEQ may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transgenic cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing NSEQ may be designed to contain signal sequences which direct secretion of the protein through a prokaryotic or eukaryotic cell membrane.

In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" form of the protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and W138) are available from the American Type Culture Collection (Manassas MD) and may be chosen to ensure the correct modification and processing of the expressed protein.

In another embodiment of the invention, natural, modified or recombinant nucleic acid sequences are ligated to a heterologous sequence resulting in translation of a fusion protein containing heterologous protein moieties in any of the aforementioned host systems. Such heterologous protein moieties facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase, maltose binding protein, thioredoxin, calmodulin binding peptide, 6-His, FLAG, c-myc, hemagglutinin, and monoclonal antibody epitopes.

In another embodiment, the nucleic acid sequences are synthesized, in whole or in part, using chemical or enzymatic methods well known in the art (Caruthers *et al.* (1980) *Nucleic Acids*

Symp. Ser. (7) 215-233; Ausubel, *supra*). For example, peptide synthesis can be performed using various solid-phase techniques (Roberge *et al.* (1995) Science 269:202-204), and machines such as the ABI 431A Peptide synthesizer (PE Biosystems) can be used to automate synthesis. If desired, the amino acid sequence may be altered during synthesis and/or combined with sequences from other proteins to produce a variant protein.

In another embodiment, the invention entails a substantially purified polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NOs:10-12 and fragments thereof.

DIAGNOSTICS and THERAPEUTICS

The polynucleotide sequences can be used in diagnosis, prognosis, treatment, prevention, and evaluation of therapies for diseases of the kidney including, but not limited, Bartter's syndrome, Gitelman syndrome, nephrolithiasis, renal amyloidosis, hypertension; primary aldosteronism; Addison's disease; renal failure; glomerulonephritis; chronic glomerulonephritis; tubulointerstitial nephritis; cystic disorders of the kidney and dysplastic malformations such as polycystic disease, renal dysplasias, and cortical or medullary cysts; inherited polycystic renal diseases (PRD), such as recessive and autosomal dominant PRD; medullary cystic disease; medullary sponge kidney and tubular dysplasia; Alport's syndrome; non-renal cancers which affect renal physiology, such as bronchogenic tumors of the lungs or tumors of the basal region of the brain; multiple myeloma; adenocarcinomas of the kidney; metastatic renal carcinoma; in addition, nephrotoxic disorders include any functional or morphologic change in the kidney produced by any pharmaceutical, chemical, or biological agent that is ingested, injected, inhaled, or absorbed.

In one preferred embodiment, the polynucleotide sequences are used for diagnostic purposes to determine the absence, presence, and excess expression of the protein. The polynucleotides may be at least 18 nucleotides long and consist of complementary RNA and DNA molecules, branched nucleic acids, and/or peptide nucleic acids (PNAs). In one alternative, the polynucleotides are used to detect and quantify gene expression in samples in which expression of NSEQ is correlated with disease. In another alternative, NSEQ can be used to detect genetic polymorphisms associated with a disease. These polymorphisms may be detected in the transcript cDNA.

The specificity of the probe is determined by whether it is made from a unique region, a regulatory region, or from a conserved motif. Both probe specificity and the stringency of diagnostic hybridization or amplification (maximal, high, intermediate, or low) will determine whether the probe identifies only naturally occurring, exactly complementary sequences, allelic variants, or related sequences. Probes designed to detect related sequences should preferably have at least 75% sequence identity to any of the nucleic acid sequences encoding PSEQ.

Methods for producing hybridization probes include the cloning of nucleic acid sequences into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by adding appropriate RNA polymerases and labeled nucleotides. Hybridization probes may incorporate nucleotides labeled by a variety of reporter groups including, but not limited to, radionuclides such as ^{32}P or ^{35}S , enzymatic labels such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, fluorescent labels, and the like. The labeled polynucleotide sequences may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; and in microarrays utilizing samples from subjects to detect altered NSEQ expression.

NSEQ can be labeled by standard methods and added to a sample from a subject under conditions suitable for the formation and detection of hybridization complexes. After incubation the sample is washed, and the signal associated with hybrid complex formation is quantitated and compared with a standard value. Standard values are derived from any control sample, typically one that is free of the suspect disease. If the amount of signal in the subject sample is altered in comparison to the standard value, then the presence of altered levels of expression in the sample indicates the presence of the disease. Qualitative and quantitative methods for comparing the hybridization complexes formed in subject samples with previously established standards are well known in the art.

Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual subject. Once the presence of disease is established and a treatment protocol is initiated, hybridization or amplification assays can be repeated on a regular basis to determine if the level of expression in the subject begins to approximate that which is observed in a healthy subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to many years.

The polynucleotides may be used for the diagnosis of a variety of diseases associated with the kidney. These include, but are not limited to, Bartter's syndrome, Gitelman syndrome, nephrolithiasis, renal amyloidosis, hypertension; primary aldosteronism; Addison's disease; renal failure; glomerulonephritis; chronic glomerulonephritis; tubulointerstitial nephritis; cystic disorders of the kidney and dysplastic malformations such as polycystic disease, renal dysplasias, and cortical or medullary cysts; inherited polycystic renal diseases (PRD), such as recessive and autosomal dominant PRD; medullary cystic disease; medullary sponge kidney and tubular dysplasia; Alport's syndrome; non-renal cancers which affect renal physiology, such as bronchogenic tumors of the

lungs or tumors of the basal region of the brain; multiple myeloma; adenocarcinomas of the kidney; metastatic renal carcinoma; in addition, nephrotoxic disorders include any functional or morphologic change in the kidney produced by any pharmaceutical, chemical, or biological agent that is ingested, injected, inhaled, or absorbed.

- 5 The polynucleotides may also be used as targets in a microarray. The microarray can be used to monitor the expression patterns of large numbers of genes simultaneously and to identify splice variants, mutations, and polymorphisms. Information derived from analyses of the expression patterns may be used to determine gene function, to understand the genetic basis of a disease, to diagnose a disease, and to develop and monitor the activities of therapeutic agents used to treat a
- 10 disease. Microarrays may also be used to detect genetic diversity, single nucleotide polymorphisms which may characterize a particular population, at the genome level.

- In yet another alternative, polynucleotides may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. Fluorescent in situ hybridization may be correlated with other physical chromosome mapping techniques and genetic map data as
- 15 described in Heinz-Ulrich *et al.* (In: Meyers; *supra*, pp. 965-968).

- In another embodiment, antibodies or antibody fragments comprising an antigen binding site that specifically binds PSEQ may be used for the diagnosis of diseases characterized by the over-or-under expression of PSEQ. A variety of protocols for measuring PSEQ, including ELISAs, RIAs, and FACS, are well known in the art and provide a basis for diagnosing altered or abnormal
- 20 levels of expression. Standard values for PSEQ expression are established by combining samples taken from healthy subjects, preferably human, with antibody to PSEQ under conditions suitable for complex formation. The amount of complex formation may be quantitated by various methods, preferably by photometric means. Quantities of PSEQ expressed in disease samples are compared with standard values. Deviation between standard and subject values establishes the parameters for
- 25 diagnosing or monitoring disease. Alternatively, one may use competitive drug screening assays in which neutralizing antibodies capable of binding PSEQ specifically compete with a test compound for binding the protein. Antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with PSEQ. In one aspect, the anti-PSEQ antibodies of the present invention can be used for treatment or monitoring therapeutic treatment for diseases of the
- 30 kidney.

 In another aspect, the NSEQ, or its complement, may be used therapeutically for the purpose of expressing mRNA and protein, or conversely to block transcription or translation of the mRNA. Expression vectors may be constructed using elements from retroviruses, adenoviruses, herpes or vaccinia viruses, or bacterial plasmids, and the like. These vectors may be used for

delivery of nucleotide sequences to a particular target organ, tissue, or cell population. Methods well known to those skilled in the art can be used to construct vectors to express nucleic acid sequences or their complements. (See, e.g., Maulik *et al.* (1997) Molecular Biotechnology, Therapeutic Applications and Strategies, Wiley-Liss, New York NY.) Alternatively, NSEQ, or its complement, may be used for somatic cell or stem cell gene therapy. Vectors may be introduced *in vivo*, *in vitro*, and *ex vivo*. For *ex vivo* therapy, vectors are introduced into stem cells taken from the subject, and the resulting transgenic cells are clonally propagated for autologous transplant back into that same subject. Delivery of NSEQ by transfection, liposome injections, or polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman *et al.* (1997) *Nature Biotechnology* 15:462-466.) Additionally, endogenous NSEQ expression may be inactivated using homologous recombination methods which insert an inactive gene sequence into the coding region or other appropriate targeted region of NSEQ. (See, e.g., Thomas *et al.* (1987) *Cell* 51: 503-512.)

Vectors containing NSEQ can be transformed into a cell or tissue to express a missing protein or to replace a nonfunctional protein. Similarly a vector constructed to express the complement of NSEQ can be transformed into a cell to downregulate the overexpression of PSEQ. Complementary or antisense sequences may consist of an oligonucleotide derived from the transcription initiation site; nucleotides between about positions -10 and +10 from the ATG are preferred. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee *et al.* In: Huber and Carr (1994) Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.)

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the cleavage of mRNA and decrease the levels of particular mRNAs, such as those comprising the polynucleotide sequences of the invention. (See, e.g., Rossi (1994) *Current Biology* 4: 469-471.) Ribozymes may cleave mRNA at specific cleavage sites. Alternatively, ribozymes may cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The construction and production of ribozymes is well known in the art and is described in Meyers (*supra*).

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiester

linkages within the backbone of the molecule. Alternatively, nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine, which are not as easily recognized by endogenous endonucleases, may be included.

5 Further, an antagonist, or an antibody that binds specifically to PSEQ may be administered to a subject to treat or prevent a disease of the kidney. The antagonist, antibody, or fragment may be used directly to inhibit the activity of the protein or indirectly to deliver a therapeutic agent to cells or tissues which express the PSEQ. An immunoconjugate comprising a PSEQ binding site of the antibody or the antagonist and a therapeutic agent may be administered to a subject in need to
10 treat or prevent disease. The therapeutic agent may be a cytotoxic agent selected from a group including, but not limited to, abrin, ricin, doxorubicin, daunorubicin, taxol, ethidium bromide, mitomycin, etoposide, teniposide, vincristine, vinblastine, colchicine, dihydroxy anthracin dione, actinomycin D, diphtheria toxin, Pseudomonas exotoxin A and 40, radioisotopes, and glucocorticoid.

Antibodies to PSEQ may be generated using methods that are well known in the art. Such
15 antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies, such as those which inhibit dimer formation, are especially preferred for therapeutic use. Monoclonal antibodies to PSEQ may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not
20 limited to, the hybridoma, the human B-cell hybridoma, and the EBV-hybridoma techniques. In addition, techniques developed for the production of chimeric antibodies can be used. (See, e.g., Pound (1998) Immunochemical Protocols, Methods Mol. Biol. Vol. 80.) Alternatively, techniques described for the production of single chain antibodies may be employed. Antibody fragments which contain specific binding sites for PSEQ may also be generated. Various immunoassays may
25 be used to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art.

Yet further, an agonist of PSEQ may be administered to a subject to treat or prevent a disease associated with decreased expression, longevity or activity of PSEQ.

30 An additional aspect of the invention relates to the administration of a pharmaceutical or sterile composition, in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic applications discussed above. Such pharmaceutical compositions may consist of PSEQ or antibodies, mimetics, agonists, antagonists, or inhibitors of the polypeptide. The compositions may be administered alone or in combination with at least one other agent, such as a stabilizing

compound, which may be administered in any sterile, biocompatible pharmaceutical carrier including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a subject alone or in combination with other agents, drugs, or hormones.

The pharmaceutical compositions utilized in this invention may be administered by any
5 number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate
10 processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA).

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays or in animal models such as mice, rats, rabbits, dogs, or pigs. An animal model may
15 also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating and
20 contrasting the ED₅₀ (the dose therapeutically effective in 50% of the population) and LD₅₀ (the dose lethal to 50% of the population) statistics. Any of the therapeutic compositions described above may be applied to any subject in need of such therapy, including, but not limited to, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

EXAMPLES

25 It is to be understood that this invention is not limited to the particular devices, machines, materials and methods described. Although particular embodiments are described, equivalent embodiments may be used to practice the invention. The described embodiments are not intended to limit the scope of the invention which is limited only by the appended claims. The examples below are provided to illustrate the subject invention and are not included for the purpose of limiting the
30 invention.

I cDNA Library Construction

The KIDNNOT 19 library, in which Incyte clones 2673009 and 2675922 were discovered, was constructed from RNA isolated from kidney tissue removed from a 65-year-old male during an exploratory laparotomy and nephroureterectomy. Pathology for the associated tumor tissue

indicated a grade 1 renal cell carcinoma, clear cell type, forming a variegated mass situated within the upper pole of the left kidney. Patient presented with abdominal pain. Patient history included benign hypertension and medications included verapamil, lisinopril, and aspirin. The frozen tissue was homogenized and lysed in TRIZOL reagent (10 g/10 ml; Life Technologies), using a
5 POLYTRON homogenizer (PT-3000; Brinkmann Instruments, Westbury NY). Following homogenization, chloroform was added to the homogenate (at a ratio of 1:5 chloroform:homogenate, v/v), and the phases separated by centrifugation. The aqueous phase was removed to a fresh tube and mixed with isopropanol. Precipitated RNA was resuspended in DEPC-treated water and treated with DNase for 25 minutes at 37°C. The RNA was re-extracted with acid phenol-chloroform, pH
10 4.7, and precipitated with 0.3M sodium acetate and 2.5 volumes 100% ethanol. The mRNA was isolated with the OLIGOTEX kit (Qiagen, Valencia CA) and used to construct the cDNA library.

The mRNA was handled according to the recommended protocols in the SUPERSCRIPT plasmid system (Life Technologies). The cDNAs were fractionated on a SEPHAROSE CL413 column (Amersham Pharmacia Biotech, Piscataway NJ), and those cDNAs exceeding 400 bp were
15 ligated into pINCY plasmid (Incyte Pharmaceuticals, Palo Alto CA). The plasmid was subsequently transformed into DH5 α competent cells (Life Technologies).

II Isolation and Sequencing of cDNA Clones

Plasmid DNA was released from the cells and purified using the REAL PREP 96 plasmid kit (Qiagen). This kit enabled the simultaneous purification of 96 samples in a 96-well block using
20 multi-channel reagent dispensers. The recommended protocol was employed except for the following changes: 1) the bacteria were cultured in 1 ml of sterile Terrific Broth (Life Technologies) with carbenicillin at 25 mg/l and glycerol at 0.4%; 2) after inoculation, the cultures were incubated for 19 hours; at the end of incubation, the cells were lysed with 0.3 ml of lysis buffer; and 3) following isopropanol precipitation, the plasmid DNA pellet was resuspended in 0.1 ml of distilled
25 water, and samples were transferred to a 96-well block for storage at 4°C.

The cDNAs were prepared using a MICROLAB 2200 (Hamilton, Reno NV) in combination with DNA ENGINE thermal cycler (PTC200; MJ Research, Watertown MA). cDNAs were sequenced by the method of Sanger *et al.* (1975, J. Mol. Biol. 94:441f) using ABI PRISM 377 DNA sequencing systems (PE Biosystems) or MEGABASE 1000 sequencing systems (Amersham
30 Pharmacia Biotech).

Most of the sequences disclosed herein were sequenced using standard ABI protocols and kits (PE Biosystems). The solution volumes were used at 0.25x -1.0x concentrations. Some of the sequences disclosed herein were sequenced using solutions and dyes from Amersham Pharmacia Biotech.

III Selection, Assembly, and Characterization of Sequences

The sequences used for coexpression analysis were assembled from EST sequences, 5' and 3' longread sequences, and full length coding sequences. Selected assembled sequences were expressed in at least three cDNA libraries.

- 5 The assembly process is described as follows. EST sequence chromatograms were processed and verified. Quality scores were obtained using PHRED (Ewing *et al.* (1998) *Genome Res.* 8:175-185; Ewing and Green (1998) *Genome Res.* 8:186-194), and edited sequences were loaded into a relational database management system (RDBMS). The sequences were clustered using BLAST with a product score of 50. All clusters of two or more sequences created a bin, and
10 each bin with its resident sequences represents one transcribed gene.

Assembly of the component sequences within each bin was performed using a modification of PHRAP, a publicly available program for assembling DNA fragments (Green, P. University of Washington Seattle WA). Bins that showed 82% identity from a local pair-wise alignment between any of the consensus sequences were merged.

- 15 Bins were annotated by screening the consensus sequence in each bin against public databases, such as GBpri and GenPept from NCBI. The annotation process involved a FASTn screen against the GenBank GBpri database. Those hits with a percent identity of greater than or equal to 75% and an alignment length of greater than or equal to 100 base pairs were recorded as homolog hits. The residual unannotated sequences were screened by FASTx against GenPept.
20 Those hits with an E value of less than or equal to 10^{-8} were recorded as homolog hits.

- Sequences were then reclustered using BLASTn and Cross-Match, a program for rapid protein and nucleic acid sequence comparison and database search (Green, *supra*), sequentially. Any BLAST alignment between a sequence and a consensus sequence with a score greater than 150 was realigned using cross-match. The sequence was added to the bin whose consensus sequence
25 gave the highest Smith-Waterman score (Smith, *supra*) among local alignments with at least 82% identity. Non-matching sequences were moved into new bins, and assembly processes were performed for the new bins.

IV Coexpression Analyses of Known Kidney Disease-Associated Genes

- Eleven known kidney disease-associated genes were selected to identify novel genes that are
30 closely associated with diseases of the kidney. These known genes were uromodulin, NKCC2, NCCT, aldolase B, ROMK1, ATP1G1, PDZK1, NPT-1, calbindin, kininogen, and CIC-Kb. The kidney disease-associated genes which were examined in this analysis and brief descriptions of their functions are listed in Table 3.

Table 3. Descriptions of Known Kidney Disease-Associated Genes

GENE	DESCRIPTION AND REFERENCES
Uromodulin	Tamm-Horsfall glycoprotein; immuno-suppressive; binds IL- 1 α , β , TNF marker for distal tubular function; marker for chronic ifosfamide (anti-neoplastic) nephrotoxicity, implicated in kidney stone formation (Hallson <u>et al.</u> (1997) Br. J. Urol. 80:533-538; MacLean <u>et al.</u> (1998) Cancer Chemother. Pharmacol. 41:413-416; Torffvit <u>et al.</u> (1998) Nephron 79:167-172)
NKCC2	Bumetanide-sensitive Na (K ⁺)-Cl ₂ co-transporter; mutant NKCC2 leads to neonatal Bartter's syndrome (hypokalaemic alkalosis, low blood pressure, hypercalcinuria); implicated in autosomal dominant polycystic kidney disease (Simon <u>et al.</u> (1996) Nat. Genet. 13:183-188; Sullivan <u>et al.</u> (1998) Physiol. Rev. 78:1165-1191)
NCCT	Thiazide-sensitive Na (K ⁺)-Cl ₂ co-transporter; mutant NCCT leads to Gitelman syndrome (hypokalaemic alkalosis, hypotension, hypocalcinuria) (Mastroianni <u>et al.</u> (1996) Am. J. Hum. Genet. 59:1019-1026)
Aldolase B	Fructose-bisphosphate aldolase; mutation in aldolase B leads to fructose intolerance and hepatorenal toxicity (Ali <u>et al.</u> (1993) Q. J. Med. 86:25-30; Ali <u>et al.</u> (1998) J. Med. Genet. 35:353-365)
ROMK1	Inwardly rectifying voltage-gated K ⁺ channel; mutation in ROMK1 leads to form of Bartter's syndrome (Yano <u>et al.</u> (1994) Mol. Pharmacol. 45:854-860; Derst <u>et al.</u> (1997) Biochem. Biophys. Res. Commun. 230:641-645)
ATP1G1	Na ⁺ /K ⁺ -ATPase gamma subunit; required for acquisition of fluid transport capacity (Jones <u>et al.</u> (1997) J. Cell Biol. 139:1545-1552; Kim <u>et al.</u> (1997) Biochim. Biophys. Acta 1350:133-135)
PDZK1	PDZ domain containing protein; co-localizes with ion channels (Kocher <u>et al.</u> (1998) Lab. Invest. 78:117-125)
NPT-1	Na ⁺ -dependent phosphate co-transporter; candidate for hereditary hypophosphatemia with hypercalcinuria (Miyamoto <u>et al.</u> (1995) Biochem. J. 305:81-85; Miyamoto <u>et al.</u> (1995) Tokushima J. Exp. Med. 42:5-9)
Calbindin	Calcium-binding protein, vitamin D-dependent; excess protein levels in spontaneously hypertensive rats; decreased protein level associated with cyclosporin A nephrotoxicity in kidney transplant patients (Kamijo <u>et al.</u> (1996) Kidney Int. Suppl. 55S:166-168; Aicher <u>et al.</u> (1998) Electrophoresis 19:1988-2003)
Kininogen	Cysteine protease inhibitor; regulates blood pressure in conjunction with renal kallikrein (Sharma <u>et al.</u> (1996) Gen. Pharmacol. 27:55-63)
ClC-Kb	Chloride channel; mutations lead to classic Bartter's syndrome (Rodriguez- Soriano (1998) Pediatr. Nephrol. 12:315-327)

From a total of 41,419 assembled gene sequences, we have identified nine novel genes that

show strong association with 11 known kidney disease-associated genes. Initially, the degree of association was measured by probability values using a cutoff p value less than 0.00001. The sequences were further examined to ensure that the genes that passed the probability test had strong association with known kidney disease-associated genes. The process was reiterated so that the initial 41,419 genes were reduced to the final nine kidney disease genes. Details of the expression patterns for the 11 known and nine novel kidney disease genes are presented in Table 4.

Table 4. Co-Expression of Nine Novel Genes and 11 Known Kidney Disease Genes
(-log p)

Name	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18
1 Aldolase B																		
2 PDZK1	9																	
3 ATP1G1	10	13																
4 Kininogen	21	9	6															
5 NKCC2	7	10	7	6														
6 NCCT	5	9	10	6	10													
7 NPT-1	1	7	6	4	0	1												
8 Uromodulin	9	13	12	7	12	13	2											
9 ROMK1	6	8	7	9	6	7	1	9										
10 CIC-Kb	5	6	6	5	6	9	0	8	8									
11 Calbindin	3	7	4	5	8	7	1	8	5	4								
12 2675922	4	5	5	4	7	7	0	6	3	4	4							
13 3534377	4	6	5	7	8	8	0	7	6	5	5	6						
14 3481942	3	7	6	5	4	5	3	5	8	4	6	3	6					
15 2911650	1	9	4	2	7	6	3	8	3	3	5	1	1	3				
16 1900433	4	6	5	5	8	9	0	7	7	10	5	5	6	5	4			
17 2580580	3	9	7	3	3	5	6	5	5	3	3	2	3	6	3	3		
18 2673009	5	12	10	5	7	7	4	7	6	5	6	7	8	9	4	6	6	
19 1399234	6	8	5	7	7	6	1	8	8	4	5	4	6	5	2	4	3	5
20 1867351	1	7	3	2	1	1	6	3	3	1	1	1	1	3	2	1	4	2

We examined genes that are coexpressed with the 11 known kidney disease-associated genes, and identified nine novel genes that are strongly coexpressed. Each of the nine novel genes is coexpressed with at least one of the 11 known genes with a p-value of less than 10e-05. The coexpression of the nine novel genes with the 11 known genes are shown in Table 4. The entries in Table 4 are the negative log of the p-value (-log p) for the coexpression of the two genes. The novel genes identified are listed by their Incyte clone numbers, and the known genes, by their names or abbreviations as shown in Table 3. For convenience, all the genes in Table 4 are assigned an identifying number, 1 to 20.

V Novel Genes Associated with Kidney Diseases

Using the co-expression analysis method, we have identified nine novel genes that exhibit strong association, or co-expression, with 11 known kidney disease-associated genes.

Nucleic acids comprising the consensus sequences of SEQ ID NOs:1-9 of the present invention were first identified from Incyte Clones 2675922, 3534377, 3481942, 2911650, 1900433, 2580580, 2673009, 1399234, and 1867351, respectively, and assembled as described in Example III. BLAST was performed for SEQ ID NOs:1-9 as described in Example VI. SEQ ID NOs:1-9 were translated and sequence identity was sought via motif searches and BLAST comparison to known sequences. SEQ ID NOs:10-12 of the present invention were encoded by the nucleic acids of SEQ ID NO:3, SEQ ID NO:5, and SEQ ID NO:7, respectively. SEQ ID NOs:10-12 were also analyzed using BLAST and other motif search tools as disclosed in Example VI. Analyses of the novel genes is as follows.

SEQ ID NO:1 (Incyte clone 2675922) is 613 nucleotides in length and has no significant known homologs in any of the public databases described in this application. SEQ ID NO:2 (Incyte clone 3534377) is 618 nucleotides in length and has no significant known homologs in any of the public databases described in this application. SEQ ID NO:3 (Incyte clone 3481942) is 512 nucleotides in length and has about 71% identity to the nucleic acid sequence of a rat kidney-specific protein (g3127192). SEQ ID NO:4 (Incyte clone 2911650) is 999 nucleotides in length and has no significant known homologs in any of the public databases described in this application. SEQ ID NO:5 (Incyte clone 1900433) is 616 nucleotides in length and has about 41% identity to the nucleic acid sequence of a human MAT8 protein (g1085025). SEQ ID NO:6 (Incyte clone 2580580) is 862 nucleotides in length and has no significant known homologs in any of the public databases described in this application. SEQ ID NO:7 (Incyte clone 2673009) is 1090 nucleotides in length and has no significant known homologs in any of the public databases described in this application. SEQ ID NO:8 (Incyte clone 1399234) is 1108 nucleotides in length and has no significant known homologs in any of the public databases described in this application. SEQ ID NO:9 (Incyte clone 186735 1) is 1290 nucleotides in length and has no significant known homologs in any of the public databases described in this application. SEQ ID NO:10 has 139 amino acids which are encoded by SEQ ID NO:3 and has about 86% identity to the amino acid sequence of a rat kidney-specific protein (g3127193). Motif analyses of SEQ ID NO:10 show two potential phosphorylation sites at residues S 19 and TI 37. SEQ ID NO:11 has 89 amino acids which are encoded by SEQ ID NO:5 and has about 71% identity to the amino acid sequence of a mouse MAT8 protein (g 1085068). Motif analyses of SEQ ID NO:11 show three potential phosphorylation sites at residues T15, S58, and S66, as well as a signal peptide sequence from

residues MI through A19, and a MAT8 family signature sequence from residue D28 through Y63. SEQ ID NO:12 has 285 amino acids which are encoded by SEQ ID NO:7. Motif analyses of SEQ ID NO:12 show nine potential phosphorylation sites at residues S27, T43, S67, T72, S87, T160, Y179, T227, and S236.

5 VI Homology Searching for Kidney Disease Genes and Their Encoded Proteins

The polynucleotide sequences, SEQ ID NOs:1-9, and polypeptide sequences, SEQ ID NOs:10-12, were queried against databases derived from sources such as GenBank and SwissProt. These databases, which contain previously identified and annotated sequences, were searched for regions of similarity using BLAST (Altschul, *supra*). BLAST searched for matches and reported
 10 only those that satisfied the probability thresholds of 10^{-25} or less for nucleotide sequences and 10^{-8} or less for polypeptide sequences.

The polypeptide sequences were also analyzed for known motif patterns using MOTIFS, SPSCAN, BLIMPS, and HMM-based protocols. MOTIFS (Genetics Computer Group, Madison WI) searches polypeptide sequences for patterns that match those defined in the Prosite Dictionary
 15 of Protein Sites and Patterns (Bairoch, *supra*) and displays the patterns found and their corresponding literature abstracts. SPSCAN (Genetics Computer Group) searches for potential signal peptide sequences using a weighted matrix method (Nielsen *et al.* (1997) Prot. Eng. 10:1-6). Hits with a score of 5 or greater were considered. BLIMPS uses a weighted matrix analysis algorithm to search for sequence similarity between the polypeptide sequences and those contained in
 20 BLOCKS, a database consisting of short amino acid segments, or blocks of 3-60 amino acids in length, compiled from the PROSITE database (Henikoff, *supra*; Bairoch, *supra*), and those in PRINTS, a protein fingerprint database based on nonredundant sequences obtained from sources such as SwissProt, GenBank, PIR, and NRL-3D (Attwood *et al.* (1997) J. Chem. Inf. Comput. Sci. 37:417-424). For the purposes of the present invention, the BLIMPS searches reported matches
 25 with a cutoff score of 1000 or greater and a cutoff probability value of 1.0×10^{-3} . HMM-based protocols were based on a probabilistic approach and searched for consensus primary structures of gene families in the protein sequences (Eddy, *supra*; Sonnhammer, *supra*). More than 500 known protein families with cutoff scores ranging from 10 to 50 bits were selected for use in this invention.

VII Labeling of Probes and Hybridization Analyses

30 Blotting

Polynucleotide sequences are isolated from a biological source and applied to a solid matrix (a blot) suitable for standard nucleic acid hybridization protocols by one of the following methods. A mixture of target nucleic acids is fractionated by electrophoresis through an 0.7% agarose gel in 1x TAE [40 mM Tris acetate, 2 mM ethylenediamine tetraacetic acid (EDTA)] running buffer and

transferred to a nylon membrane by capillary transfer using 20x saline sodium citrate (SSC).

Alternatively, the target nucleic acids are individually ligated to a vector and inserted into bacterial host cells to form a library. Target nucleic acids are arranged on a blot by one of the following methods. In the first method, bacterial cells containing individual clones are robotically picked and

- 5 arranged on a nylon membrane. The membrane is placed on bacterial growth medium, LB agar containing carbenicillin, and incubated at 37°C for 16 hours. Bacterial colonies are denatured, neutralized, and digested with proteinase K. Nylon membranes are exposed to UV irradiation in a STRATALINKER UV-crosslinker (Stratagene, La Jolla CA) to cross-link DNA to the membrane.

- In the second method, target nucleic acids are amplified from bacterial vectors by thirty
10 cycles of PCR using primers complementary to vector sequences flanking the insert. Amplified target nucleic acids are purified using SEPHACRYL-400 (Amersham Pharmacia Biotech). Purified target nucleic acids are robotically arrayed onto a glass microscope slide. The slide was previously coated with 0.05% aminopropyl silane (Sigma-Aldrich, St. Louis MO) and cured at 110°C. The arrayed glass slide (microarray) is exposed to UV irradiation in a STRATALINKER
15 UV-crosslinker (Stratagene).

Probe Preparation

- cDNA probe sequences are made from mRNA templates. Five micrograms of mRNA is mixed with 1 µg random primer (Life Technologies), incubated at 70°C for 10 minutes, and lyophilized. The lyophilized sample is resuspended in 50 µl of 1x first strand buffer (cDNA
20 Synthesis system; Life Technologies) containing a dNTP mix, [α -³²P]dCTP, dithiothreitol, and MMLV reverse transcriptase (Stratagene), and incubated at 42°C for 1-2 hours. After incubation, the probe is diluted with 42 µl dH₂O, heated to 95°C for 3 minutes, and cooled on ice. mRNA in the probe is removed by alkaline degradation. The probe is neutralized, and degraded mRNA and unincorporated nucleotides are removed using a PROBEQUANT G-50 microcolumn (Amersham
25 Pharmacia Biotech). Probes can be labeled with fluorescent markers, Cy3-dCTP or Cy5-dCTP (Amersham Pharmacia Biotech), in place of the radionuclide, [³²P]dCTP.

Hybridization

- Hybridization is carried out at 65°C in a hybridization buffer containing 0.5 M sodium phosphate (pH 7.2), 7% SDS, and 1 mM EDTA. After the blot is incubated in hybridization buffer
30 at 65°C for at least 2 hours, the buffer is replaced with 10 ml of fresh buffer containing the probe sequences. After incubation at 65°C for 18 hours, the hybridization buffer is removed, and the blot is washed sequentially under increasingly stringent conditions, up to 40 mM sodium phosphate, 1% SDS, 1 mM EDTA at 65°C. To detect signal produced by a radiolabeled probe hybridized on a membrane, the blot is exposed to a PHOSPHORIMAGER cassette (Amersham Pharmacia Biotech),

and the image is analyzed using IMAGEQUANT data analysis software (Amersham Pharmacia Biotech). To detect signals produced by a fluorescent probe hybridized on a microarray, the blot is examined by confocal laser microscopy, and images are collected and analyzed using GEMTOOLS gene expression analysis software (Incyte Pharmaceuticals).

5 **VIII Production of Specific Antibodies**

SEQ ID NOs:10-12, or portions thereof, substantially purified using polyacrylamide gel electrophoresis or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols as described in Pound (supra).

- Alternatively, the amino acid sequence is analyzed using LASERGENE software
- 10 (DNASTAR, Madison WI) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for, selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. Typically, oligopeptides 15 residues in length are synthesized using an ABI 431A Peptide synthesizer (PE Biosystems) using Fmoc-chemistry and coupled to
- 15 keyhole limpet hemocyanin (KLH, Sigma-Aldrich) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (Ausubel, supra) to increase immunogenicity. Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for anti-peptide activity by, for example, binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated
- 20 goat anti-rabbit IgG.

What is claimed is:

1. A substantially purified polynucleotide comprising a gene that is coexpressed with one or more known kidney disease-associated genes in a plurality of biological samples, wherein each known kidney disease-associated gene is selected from the group consisting of uromodulin, NKCC2
5 (bumetanide-sensitive Na-K-Cl cotransporter 2), NCCT (thiazine-sensitive Na-Cl cotransporter), aldolase B, ROMK1 (inwardly-rectifying voltage-gated K channel), ATP1G1 (Na-K ATPase gamma subunit), PDZK1 (PDZ domain-containing protein), NPT-1 (Na-dependent phosphate cotransporter), calbindin, kininogen, and CIC-Kb (chloride channel).
2. The polynucleotide of claim 1, comprising a polynucleotide sequence selected from the
10 group consisting of:
 - (a) a polynucleotide sequence selected from the group consisting of SEQ ID NOs:1-9
 - (b) a polynucleotide encoding a polypeptide sequence selected from the group consisting of SEQ ID NOs:10-12;
 - (c) a polynucleotide sequence having at least 75% identity to the polynucleotide sequence of
15 (a)
or (b);
 - (d) a polynucleotide sequence which is complementary to the polynucleotide sequence of (a),
(b)
or (c);
 - 20 (e) a polynucleotide sequence comprising at least 18 sequential nucleotides of the polynucleotide sequence of (a), (b), (c), or (d); and
 - (f) a polynucleotide which hybridizes under stringent conditions to the polynucleotide of (a),
(b),
(c), (d), or (e).
- 25 3. A substantially purified polypeptide comprising the gene product of a gene that is coexpressed with one or more known kidney disease-associated genes in a plurality of biological samples, wherein each known kidney disease-associated gene is selected from the group consisting of uromodulin, NKCC2, NCCT, aldolase B, ROMK1, ATP1G1, PDZK1, NPT-1, calbindin, kininogen, and CIC-Kb.
- 30 4. The polypeptide of claim 3, comprising a polypeptide sequence selected from the group consisting of:
 - (a) the polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NOs:10-12;
 - (b) a polypeptide sequence having at least 85% identity to the polypeptide sequence of (a);

and

(c) a polypeptide sequence comprising at least 6 sequential amino acids of the polypeptide sequence of (a) or (b).

- 5 5. An expression vector comprising the polynucleotide of claim 2.
6. A host cell comprising the expression vector of claim 5.
7. A pharmaceutical composition comprising the polynucleotide of claim 2 in conjunction
with a suitable pharmaceutical carrier.
8. A pharmaceutical composition comprising the polypeptide of claim 3 in conjunction with
a suitable pharmaceutical carrier.
- 10 9. An antibody or antibody fragment comprising an antigen binding site, wherein the
antigen
binding site specifically binds to the polypeptide of claim 4.
10. An immunoconjugate comprising the antigen binding site of the antibody or antibody
fragment of claim 9 joined to a therapeutic agent.
- 15 11. A method for diagnosing a disease or condition associated with the altered expression of
a gene that is coexpressed with one or more known kidney disease-associated genes, wherein each
known kidney disease-associated gene is selected from the group consisting of uromodulin, NKCC2,
NCCT, aldolase B, ROMK1, ATP1G1, PDZK1, NPT-1, calbindin, kininogen, and CIC-Kb, the
method comprising the steps of:
20 (a) providing a biological sample;
 (b) hybridizing a polynucleotide of claim 2 to the biological sample under conditions
effective to form one or more hybridization complexes;
 (c) detecting the hybridization complexes; and
 (d) comparing the levels of the hybridization complexes with the level of hybridization
25 complexes in a non-diseased sample, wherein the altered level of hybridization complexes compared
with the level of hybridization complexes of a nondiseased sample correlates with the presence of the
disease or condition.
12. A method for treating or preventing a disease associated with the altered expression of a
gene that is coexpressed with one or more known kidney disease-associated genes in a subject in
30 need, wherein each known kidney disease-associated gene is selected from the group consisting of
uromodulin, NKCC2, NCCT, aldolase B, ROMK1, ATP1G1, PDZK1, NPT-1, calbindin,
kininogen, and CIC-Kb, the method comprising the step of administering to the subject in need the
pharmaceutical composition of claim 7 in an amount effective for treating or preventing the disease.
13. A method for treating or preventing a disease associated with the altered expression of a

gene that is coexpressed with one or more known kidney disease-associated genes in a subject in need wherein each known kidney disease-associated gene is selected from the group consisting of uromodulin, NKCC2, NCCT, aldolase B, ROMK1, ATP1G1, PDZK1, NPT-1, calbindin, kininogen, and CIC-Kb, the method comprising the step of administering to the subject in need the pharmaceutical composition of claim 8 in an amount effective for treating or preventing the disease.

14. A method for treating or preventing a disease associated with the altered expression of a gene that is coexpressed with one or more known kidney disease-associated genes in a subject in need wherein each known kidney disease-associated gene is selected from the group consisting of uromodulin, NKCC2, NCCT, aldolase B, ROMK1, ATP1G1, PDZK1, NPT-1, calbindin, kininogen, and CIC-Kb, the method comprising the step of administering to the subject in need the antibody or the antibody fragment of claim 9 in an amount effective for treating or preventing the disease.

15. A method for treating or preventing a disease associated with the altered expression of a gene that is coexpressed with one or more known kidney disease-associated genes in a subject in need, wherein each known kidney disease-associated gene is selected from the group consisting of uromodulin, NKCC2, NCCT, aldolase B, ROMK1, ATP1G1, PDZK1, NPT-1, calbindin, kininogen, and CIC-Kb, the method comprising the step of administering to the subject in need the immunoconjugate of claim 10 in an amount effective for treating or preventing the disease.

16. A method for treating or preventing a disease associated with the altered expression of a gene that is coexpressed with one or more known kidney disease-associated genes in a subject in need, wherein each known kidney disease-associated gene is selected from the group consisting of uromodulin, NKCC2, NCCT, aldolase B, ROMK1, ATP1G1, PDZK1, NPT-1, calbindin, kininogen, and CIC-Kb, the method comprising the step of administering to the subject in need the polynucleotide sequence of claim 2 in an amount effective for treating or preventing the disease.

SEQUENCE LISTING

<110> INCYTE PHARMACEUTICALS, INC.
 WALKER, Michael, G.
 VOLKMUTH, Wayne
 KLINGLER, Tod, M.
 AZIMZAI, Yalda
 YUE, Henry

<120> GENES ASSOCIATED WITH DISEASES OF THE KIDNEY

<130> PB-0010 PCT

<140> To Be Assigned

<141> Herewith

<150> 09/289,349

<151> 1999-04-09

<160> 12

<170> PERL Program

<210> 1

<211> 613

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 2675922CT1

<400> 1
 gggcaagggg cagttggtga acttgctgcc tccagagaac cttccctggt gtggaggcag 60
 ccagggaccc aggatgctcc ggacctgtta cgtgctctgt tcccaagctg gtccccctc 120
 caggggctgg cagtcctga gctttgatgg cggggccttc caccttaagg gcacaggaga 180
 gctgacacgg gccttgctgg ttctcgggt gtgtgcctgg cccccactcg tcactcacgg 240
 gctgttgctc caggcctggt ctgcggcact cctgggctcc cggctctcag gcgcatttct 300
 ccgagcatcc gtctatgggc agtttgtggc tggtagagaca gcagaggagg tgaagggctg 360
 cgtgcagcac tgcggacct cagcctccga cactgctgg cagtgccac tgaggaggag 420
 ccggactctg ctgccaagag tgggtgagta gggagccagg gccaggagg gctgggagga 480
 cgcaggaagg ggctttgctg ttcgggccct gacacctgct ggctgggcag tcacgcgtgg 540
 tattacggga cctcggtgct atgctgcggt gtgtggacct gtcaaggggc ttctggagcc 600
 cccagcctgg tga 613

<210> 2

<211> 618

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 3534377CT1

<400> 2
 gtagatgctt agactacttt gaactgaagt atgtgcagtc tgccatctca cattaaaatg 60
 taggcatttt gtcaattgct tttctttcat ctgcacaaga ggaaggagag aacgaatcaa 120
 tacaaccact cttttccttg agactgcaaa gaaaatggt ctatagtttg atggttctac 180
 ttcccagatg ctacctctca gatttattct caacagaaaa ttttttgatt acagcagacc 240
 agatctttat ctgtcaataa gttaaaaaag ataactctgg ctggatgtgg tggctcactc 300
 ctgtaattcc agcacttcgg gaggccaaga caggaggatt gcttgagccc aggaatttga 360

WO 00/61622

```

gaccagcctg ggcaacatgg cgaaacccca atctctttat tttttgtttt tcgacataga 420
gtctcactct tgtcatccag gctggagtgc agtgccgtga tctcagctca ttgcactccg 480
cctcccgggt tcaagcaatt ctgcttcagc ctcccagta gctgggatga caggcatgtg 540
tcacatgcc cggccaattt tttttttttt ttcttgatt ttagtagag acaggtttca 600
ccatgttggc caggctgg                                     618

```

<210> 3
 <211> 521
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 3481942CB1

```

<400> 3
tctggagctg ctggctggag aggaggggtg acgaagctct ctctagaaag acatcctgag 60
aggacttggc aggcctgaac atgcattggc tgcgaaaagt tcagggaact tgcaccctgt 120
ggggtactca gatgtccagc cgcactctct acattaatag taggcaactg gtgtccctgc 180
agtggggcca ccaggaagtg cgggccaagt ttaactttgc tagtgatgtg ttggatcact 240
gggtgacat ggagaaggct ggcaagcgac tcccagccc agccctgtgg tgggtgaatg 300
ggaaggggaa ggaattaatg tggaaattca gagaactgag tgaaaacagc cagcaggcag 360
ccaacgtcct ctcgggagcc tgtggcctgc agcgtgggga tcgtgtggca gtggtgctgc 420
cccagtgcc tgagtgggtg ctggtgatcc tgggctgcat tcgagcaggg ctcacttta 480
tgcttggaaac catcagatga gatccactga catactgtat a 521

```

<210> 4
 <211> 999
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 2911650CT1

```

<400> 4
tggtagtcac cagtgaaga catttgaggt taagacagca agtccttgac aaatatgttc 60
atgtctatatt ggttctagtt ctataaaaat atgaacattg ggactcagag aaaatgggga 120
aaataaagt gattcaggtt atcagtgaat tgatggtata gattacagca aatctggata 180
tatattgatg ttactgcatt tgtaaatgtc ctcccattaa acagaaaatg tggctaaaat 240
ccctggcctg gaactgaact agtttaaggc aggtgtaaga atagtgggag gaaagtgtgt 300
gaaagttaa agaatgccct caatccatga acgagaggga ggatgtgtgc tttaattatt 360
tagaagggtt ttttttcctt gtctgttgat aattttatgg aagggttgct tagatctcca 420
ttcttataaa aatattacat gtcagtgtag ttagatatta tctcttttag ttattatact 480
tgctattttt actgtatagt gtggtataat caacaaaaaa taatgccacg ggcattgtta 540
caccttttct gttgcactat taaattcttt tcacagtatt catatcaatg ctaatttgaa 600
tgtgatgcca attaaaaatc ttgttcattt atattgtata tgggtacaagg acgtagcata 660
agatccaaaa aaaattttgt attgtcattt agcatatcaa tttcagccaa atttgggaaga 720
cttgatcatc ttatcttttg ctctacacac tcaaaacaaa tattgcagca gaaatatcac 780
cttaaaaaata tcttatttta tathtagata atattgaaat cacagtctat taaaattgga 840
aatttaattc aaataaaaat caaacaatat agttgtttca atttatctaa atactgggc 900
ttaagagtgc ctaagagtgt tctcgttttt aagagtgtct taaaaacgaa tatatgtata 960
agtcaacaaa tcatataata tgaaataaat agtctctggg 999

```

<210> 5
 <211> 616
 <212> DNA
 <213> Homo sapiens

WO 00/61622

<220>

<221> misc_feature

<223> Incyte ID No.: 1900433CB1

<400> 5

```

gccagctcag gtagagccctc gccaaaggtga cctcgcagga cactggtgaa ggagcagtga 60
ggaacctgca gagtcacaca gttgctgacc aattgagctg tgagcctgga gcagatccgt 120
gggctgcaga ccccgcccc agtgctctct cccctgcagc cctgccccctc gaactgtgac 180
atggagagag tgacctgggc ccttctccta ctggcaggcc tgactgcctt ggaagccaat 240
gacccatttg ccaataaaga cgatcccttc tactatgact ggaaaaacct gcagctgagc 300
ggactgatct gcggagggtc cctggccatt gctgggacg cggcagttct gagtggcaaa 360
tgcaaatata agagcagcca gaagcagcac agtcctgtac ctgagaaggc catcccatc 420
atcactccag gctctgccac tactgtctga gcacaggact ggctccagg gatggcctga 480
agcctaacac tggccccag cacctcctcc cctgggaggc cttatcctca aggaaggact 540
tctctcaag ggcaggctgt taggccccct tctgatcagg aggcctcttt atgaattaaa 600
ctgccccac ccccc

```

<210> 6

<211> 862

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 2580580CT1

<400> 6

```

gttgcaattg cactactgat tttatcaggg atctggcaac gtagaagaaa gaacaaagaa 60
ccatctgaag tggatgacgc tgaagataag tgtgaaaaca tgatcacaat tgaatatggc 120
atccccctctg atccccctgga catgaaggga gggcatatta atgatgcctt catgacagag 180
gatgagaggc tcacccctct ctgaagggtc gttgttctgc ttctcaaga aattaaacat 240
ttgtttctgt gtgactgtc agcatcctga aataccaaga gcagatcata tattttgttt 300
caccattctt cttttgtaat aaattttgaa tgtgcttgaa agtgaaaagc aatcaattat 360
acccaccaac accactgaaa tcataagcta ttcacgactc aaaatattct aaaaatattt 420
tctgacagta tagtgtata atgtggcatc gtggtatttg tagttattga ttttaagcatt 480
tttagaata agatcaggca tatgtatata ttttcacact tcaaagacct aaggaaaaat 540
aaattttcca gtggagaata catataatat ggtgtagaaa tcattgaaaa tggatccttt 600
ttgacgatca cttatatcac tctgtatatg actaagtata caaaagttag aagtaattat 660
tgtaaatgga tggataaaaa tgggaattact catatacagg gtggaatttt atcctgttat 720
cacaccaaca gttgattata tattttctga atatcagccc ctaataggac aattctattt 780
gttgaccatt tctacaattt gtaaaagtcc aatctgtgct aacttaataa agtaataatc 840
atctcttaaa aaaaaaaaaa aa

```

<210> 7

<211> 1090

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 2673009CB1

<400> 7

```

tgccacctga gcgcgctcc ctctcaggat gaaggtgacg gtgggcccag acccttccct 60
ggtctaccga cctgatgtgg acccagaggt ggccaaagac aaggccagct tccggaacta 120
cacgtcaggc cccctcctgg accgtgtctt caccacctac aagctcatgc acacgcacca 180
gacagtggac ttcgtcagga gcaagcatgc ccagtttggg ggcttctcct acaagaaaaat 240
gacagtcatg gaggcctgg acctgctgga tgggctggtg gatgagtcgg accggacgt 300
agatttcccc aactccttc atgccttcca gacagcggag ggcacccgga aggccaccc 360
agacaaggac tggttccacc tcgtcgggct cctgcacgac ctggggaagg tcctggccct 420
gttcggggag cccagtgagg ctgtcgtcgg cgacaccttc cccgtcggat gccgtccgca 480

```

```

ggcctccgtg gttttctgcg actccacctt ccaggacaac cctgacctcc aggatcctcg 540
atacagcaca gagctcggga tgtatcagcc ccactgtggg ctcgacaggg tctcatgtc 600
ctggggccat gatgagtaca tgtaccaggt gatgaagttt aacaagttct cactgcccc 660
tgaggctttc tacatgatcc ggttccactc cttctacccc tggcacacgg gccgcgacta 720
ccagcagctg tgcagccagc aggacctggc catgtctgcc tgggtgcggg agttcaacaa 780
gttcgacctc tacaccaagt gcccggacct gccggacctg gacaagctgc ggcctacta 840
ccaggggctc attgacaagt actgccctgg cctcctgagc tggtgacctc cctgccacc 900
aagctgctgc tggacctagg cctggccctc cgcctgcctg gagaggcctg gccctgggca 960
aacagccgcc atcagggttc acctcggtgg gggacccac tcacccctt agggctcgca 1020
cccctcacgg caacttgtgc ctggcgtaa taaagacctg gaaggatgtt gtgcttctga 1080
aaaaaaaaa 1090

```

<210> 8
 <211> 1108
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 1399234CT1

```

<400> 8
aaactgacct gccaggagc ccctgggaac agggggcgga gctccggcta gaggggactc 60
ctgtgtgggc gggcaggtct ggagcctggg ccaggtgtg gcctgctggg ggacagctcc 120
gggggagagc tgtggggaga acagcgtctt agggaggcag gaggcaggcg gcaggctcct 180
ccccagcagc ctgcagggca tcaggacaga gggggaagga ggagacagaa gggaaagaag 240
gagatagagg gggaaggagg aaacagcgcg gcttctgctg aagccagtac aagcctgggt 300
atctggcttg acccgccac acggaggcct cccagcggtt ttcttttcc cgagaagagc 360
tccagctcgc aggtccttag aacacggcag agcaggagca tctcaggaa caacggccag 420
ctccttggcg ctgtccccag cccacaggc ctgctgcggc catccgcaa cgggcatttc 480
cttgaacttt tgagagtgcc tttgaccagc tgttcgcagc tgggaaactc caacttttga 540
agtcagagct tggagcggcc cccgcaaggg cgtggctcaa accctccca gagctgggag 600
ccattgctta tgcaagcccg tttcttttga tgtaaagatg gaagtcgtta ctatatttta 660
ataatgcaaa tacatctttt aaaataagtt aacatttctt accaccagat ggatcaggct 720
ttgaatttaa tcatgtaaat gtttgtaatt ttatgtcatt ttgttaaaat gggacgcttt 780
caattggttt ccaagaaaga tgatacctct gcattttctg gtggaaaagg tgtaataccc 840
ttaatgagat caaagtgtta ggggaaaaaa attccaaaag tagttacaag ctatatcaat 900
gtcaaagtaa atgcacttca tcaaagctaa gaagtcacag gaattgttct caggttttta 960
aaaaaatttt tctgaattc aggaagtgtc ttctgaatag cagctagcca aataaagcgg 1020
tgtgtgtgta ctgcagctgt aggtgaactt aaaaataata ataaaaagaa caaataaagc 1080
agtgtgtacc agccaaaaaa aaaaaaa 1108

```

<210> 9
 <211> 1290
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 1867351CB1

```

<400> 9
tctctagctc ctgggagagt gctccctgga gcaccaagc cagcgtggtt gggatcatcg 60
gtgttcgtga aggagtgagt ggaggggcac tctgcgataa gatttctttt atttattcac 120
tgtagcaata gtgtcctgaa ttaactttct ctccactatt agcacatatt cctttttatac 180
atagcccttt ataaaaatga aaaaaaaaaa tcccttttaa gctgctaagt tcttttttcc 240
tcccagggtg ccctgaaaac cttgaaggaa ttttaacgaa cgatgttgga aagacaggcg 300
agcctcagtc agatcagcag atgcgccaag aagaaccttt gccggaacat ccacaggacg 360
gcgctaaatt gtccaggaaa cagctgggtc tgccggcgagg gcttctgctc ctgggggtct 420
tcttaattct gctggtgggg atttttagtga gattctatgt cagaattcag tgacgtggta 480
ggaaagaaag tcagggtcaag tgatgctttt gagcttacac acaattcaca ggcccaccag 540

```

WO 00/61622

```

tgacaattta ctgtgagtta atgtcattca ggtgtgccca tggattttga gggctggaaa 600
tgcaaagaca catttttcta taaaaagaaa aagcaactaa ggtaaaaagc tatattgtgg 660
cccaagacac tgtctgaaag atgacatgag tagtaattca ccactatctg aaccaagcaa 720
ggatcaatgt gctgactgca ttggccaatg gctttgatac ttctgctatt tttttagaca 780
caaaccata aactaactgc ttaagaattc atactgcttg aattatgtaa aatatatttt 840
acagtatata tttccttggg ccttagatta ctattcactg ggcaaatggg atttgttttt 900
tttttttttt tttttttaat agacggaagt cttgctctgt catgcaggct ggagtgcggg 960
gggtgcgatca tagctcactg cagcctcgaa ctcttgggct tcaagcaatc ctctgtgtgc 1020
agccaccaga gtagctgaga ctacaggggt atgccaccat gccagctgg catttgtaa 1080
tcttcatttg aggtctagat ctaggcactg tggacactga aaaacagttg ggaaatcttt 1140
cgagctgtgg aaatccaaac aaagactgat aattcctggg aggggtgtgt gcgtgacgta 1200
ctgcagcctc aacctcctgg gctcaagtga tcctcccacc tcagcctcct gagtagctga 1260
gaccacaggc gtgtgcccac acgcctagct 1290

```

<210> 10
 <211> 139
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 3481942CD1

<400> 10
 Met His Trp Leu Arg Lys Val Gln Gly Leu Cys Thr Leu Trp Gly
 1 5 10 15
 Thr Gln Met Ser Ser Arg Thr Leu Tyr Ile Asn Ser Arg Gln Leu
 20 25 30
 Val Ser Leu Gln Trp Gly His Gln Glu Val Pro Ala Lys Phe Asn
 35 40 45
 Phe Ala Ser Asp Val Leu Asp His Trp Ala Asp Met Glu Lys Ala
 50 55 60
 Gly Lys Arg Leu Pro Ser Pro Ala Leu Trp Trp Val Asn Gly Lys
 65 70 75
 Gly Lys Glu Leu Met Trp Asn Phe Arg Glu Leu Ser Glu Asn Ser
 80 85 90
 Gln Gln Ala Ala Asn Val Leu Ser Gly Ala Cys Gly Leu Gln Arg
 95 100 105
 Gly Asp Arg Val Ala Val Val Leu Pro Arg Val Pro Glu Trp Trp
 110 115 120
 Leu Val Ile Leu Gly Cys Ile Arg Ala Gly Leu Ile Phe Met Pro
 125 130 135
 Gly Thr Ile Arg

<210> 11
 <211> 89
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 1900433CD1

<400> 11
 Met Glu Arg Val Thr Leu Ala Leu Leu Leu Ala Gly Leu Thr
 1 5 10 15
 Ala Leu Glu Ala Asn Asp Pro Phe Ala Asn Lys Asp Asp Pro Phe
 20 25 30
 Tyr Tyr Asp Trp Lys Asn Leu Gln Leu Ser Gly Leu Ile Cys Gly

	35		40		45
Gly	Leu	Leu	Ala	Ile	Ala
	50		55		60
Cys	Lys	Tyr	Lys	Ser	Ser
	65		70		75
Lys	Ala	Ile	Pro	Leu	Ile
	80		85		

<210> 12
 <211> 285
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 2673009CD1

<400> 12
 Met Lys Val Thr Val Gly Pro Asp Pro Ser Leu Val Tyr Arg Pro
 1 5 10 15
 Asp Val Asp Pro Glu Val Ala Lys Asp Lys Ala Ser Phe Arg Asn
 20 25 30
 Tyr Thr Ser Gly Pro Leu Leu Asp Arg Val Phe Thr Thr Tyr Lys
 35 40 45
 Leu Met His Thr His Gln Thr Val Asp Phe Val Arg Ser Lys His
 50 55 60
 Ala Gln Phe Gly Gly Phe Ser Tyr Lys Lys Met Thr Val Met Glu
 65 70 75
 Ala Val Asp Leu Leu Asp Gly Leu Val Asp Glu Ser Asp Pro Asp
 80 85 90
 Val Asp Phe Pro Asn Ser Phe His Ala Phe Gln Thr Ala Glu Gly
 95 100 105
 Ile Arg Lys Ala His Pro Asp Lys Asp Trp Phe His Leu Val Gly
 110 115 120
 Leu Leu His Asp Leu Gly Lys Val Leu Ala Leu Phe Gly Glu Pro
 125 130 135
 Gln Trp Ala Val Val Gly Asp Thr Phe Pro Val Gly Cys Arg Pro
 140 145 150
 Gln Ala Ser Val Val Phe Cys Asp Ser Thr Phe Gln Asp Asn Pro
 155 160 165
 Asp Leu Gln Asp Pro Arg Tyr Ser Thr Glu Leu Gly Met Tyr Gln
 170 175 180
 Pro His Cys Gly Leu Asp Arg Val Leu Met Ser Trp Gly His Asp
 185 190 195
 Glu Tyr Met Tyr Gln Val Met Lys Phe Asn Lys Phe Ser Leu Pro
 200 205 210
 Pro Glu Ala Phe Tyr Met Ile Arg Phe His Ser Phe Tyr Pro Trp
 215 220 225
 His Thr Gly Arg Asp Tyr Gln Gln Leu Cys Ser Gln Gln Asp Leu
 230 235 240
 Ala Met Leu Pro Trp Val Arg Glu Phe Asn Lys Phe Asp Leu Tyr
 245 250 255
 Thr Lys Cys Pro Asp Leu Pro Asp Val Asp Lys Leu Arg Pro Tyr
 260 265 270
 Tyr Gln Gly Leu Ile Asp Lys Tyr Cys Pro Gly Ile Leu Ser Trp
 275 280 285

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
19 October 2000 (19.10.2000)

PCT

(10) International Publication Number
WO 00/61622 A3

(51) International Patent Classification⁷: C07K 14/47,
C12N 15/12, C12Q 1/68, C12N 15/10, C07K 16/18,
G01N 33/53, A61K 38/17, A61P 13/12

2045 Rock Springs Drive, Hayward, CA 94545 (US). YUE,
Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087
(US).

(21) International Application Number: PCT/US00/08260

(74) Agents: MURRY, Lynn, E. et al.; Incyte Pharmaceuticals,
Inc., 3160 Porter Drive, Palo Alto, CA 94304 (US).

(22) International Filing Date: 28 March 2000 (28.03.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/289,349 9 April 1999 (09.04.1999) US

(63) Related by continuation (CON) or continuation-in-part
(CIP) to earlier application:
US 09/289,349 (CIP)
Filed on 9 April 1999 (09.04.1999)

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ,
BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE,
ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,
MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD,
SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ,
VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): INCYTE
PHARMACEUTICALS, INC. [US/US]; 3160 Porter
Drive, Palo Alto, CA 94304 (US).

Published:

— With international search report.

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): WALKER, Michael,
G. [CA/US]; Unit 80, 1050 Borregas Avenue, Sunnyvale,
CA 94089 (US). VOLKMUTH, Wayne [US/US]; Apt.
613, 5916 North Las Virgenes Road, Calabasas, CA 91302
(US). KLINGLER, Tod, M. [US/US]; 28 Dover Court,
San Carlos, CA 94070 (US). AZIMZAI, Yalda [US/US];

(88) Date of publication of the international search report:
5 July 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 00/61622 A3

(54) Title: GENES ASSOCIATED WITH DISEASES OF THE KIDNEY

(57) Abstract: The invention provides novel kidney disease-associated genes and polypeptides encoded by those genes. The invention also provides expression vectors, host cells, and antibodies. The invention further provides methods for diagnosing, treating or preventing diseases of the kidney.

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/US 00/08260

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/47 C12N15/12 C12Q1/68 C12N15/10 C07K16/18
G01N33/53 A61K38/17 A61P13/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>EL-DAHR SAMIR S ET AL: "Developmental activation and segment-specific co-expression of kininogen and bradykinin (BK) B-2-receptors during rat nephrogenesis." PEDIATRIC RESEARCH, vol. 39, no. 4 PART 2, 1996, page 360A XP000956025 Joint Meeting of the American Pediatric Society and the Society for Pediatric Research; Washington, D.C., USA; May 6-10, 1996 ISSN: 0031-3998 abstract</p> <p>---</p> <p>-/--</p>	1

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

13 October 2000

Date of mailing of the international search report

17. 1. 01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Mateo Rosell, A.M.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/08260

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>TREMER LIISA ET AL: "Co-expression of p75NTR- and calbindin-immunoreactivity in cholinergic neurons of the raccoon basal forebrain." BRAIN RESEARCH, vol. 797, no. 2, 29 June 1998 (1998-06-29), pages 351-356, XP000956023 ISSN: 0006-8993 the whole document</p> <p>---</p>	1
X	<p>ICHIKAWA HIROYUKI ET AL: "S100 protein-immunoreactive primary sensory neurons in the trigeminal and dorsal root ganglia of the rat." BRAIN RESEARCH, vol. 748, no. 1-2, 1997, pages 253-257, XP000956022 ISSN: 0006-8993 the whole document</p> <p>---</p>	1
X	<p>KOSTER JOSEPH C ET AL: "Assembly of ROMK1 (Kir 1.1a) inward rectifier K⁺ channel subunits involves multiple interaction sites." BIOPHYSICAL JOURNAL, vol. 74, no. 4, April 1998 (1998-04), pages 1821-1829, XP000956021 ISSN: 0006-3495 the whole document</p> <p>---</p>	1
X	<p>WO 99 06439 A (LACROIX BRUNO ;DUCLERT AYMERIC (FR); GENSET (FR); DUMAS MILNE EDWA) 11 February 1999 (1999-02-11) SEQ.ID.N.77 abstract; tables II,III</p> <p>---</p>	2,4
P,X	<p>DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES, 2 January 2000 (2000-01-02), XP002149913 HINXTON, GB AC = U80018. Human kidney and liver proline oxidase 1 (HsPOX1) mRNA, complete cds. abstract</p> <p>---</p>	2,4
P,X	<p>WALKER MICHAEL G ET AL: "Prediction of gene function by genome-scale expression analysis: Prostate cancer-associated genes." GENOME RESEARCH, vol. 9, no. 12, December 1999 (1999-12), pages 1198-1203, XP000872154 ISSN: 1088-9051 the whole document</p> <p>---</p>	1,11

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/08260

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	VIRLON BERANGERE ET AL: "Serial microanalysis of renal transcriptomes." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 96, no. 26, 21 December 1999 (1999-12-21), pages 15286-15291, XP002149914 Dec. 21, 1999 ISSN: 0027-8424 the whole document	1,11
P,X	HEYER LAURIE J ET AL: "Exploring expression data: Identification and analysis of coexpressed genes." GENOME RESEARCH, vol. 9, no. 11, November 1999 (1999-11), pages 1106-1115, XP002149915 ISSN: 1088-9051 the whole document	1,11
T	YANO NAOHIRO ET AL: "Comprehensive gene expression profile of the adult human renal cortex: Analysis by cDNA array hybridization." KIDNEY INTERNATIONAL, vol. 57, no. 4, April 2000 (2000-04), pages 1452-1459, XP000952424 ISSN: 0085-2538 the whole document	1,11

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 00/08260

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 12-16 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

2, 4-7, 9-12, 14-16 all partially and 1,3,8 and 13 completely

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 2, 4-7,9-12,14-16 all partially and 1,3, 8 and 13 completely

A substantially purified polynucleotide comprising a gene comprising a polynucleotide from SEQ.ID.N.1 that is co-expressed with one or more known kidney disease-associated genes in a plurality of biological samples, the corresponding purified polypeptide, an expression vector, a host cell, a pharmaceutical composition, an antibody or antibody fragment, and immunoconjugate; a method for diagnosing the disease associated with such gene and a method of treatment for such disease.

2. Claims: 2, 4-7,9-12,14-16 all partially and 1,3, 8 and 13 completely

A substantially purified polynucleotide comprising a gene comprising a polynucleotide from SEQ.ID.N.2 that is co-expressed with one or more known kidney disease-associated genes in a plurality of biological samples, the corresponding purified polypeptide, an expression vector, a host cell, a pharmaceutical composition, an antibody or antibody fragment, and immunoconjugate; a method for diagnosing the disease associated with such gene and a method of treatment for such disease.

3. Claims: 2, 4-7,9-12,14-16 all partially and 1,3, 8 and 13 completely

A substantially purified polynucleotide comprising a gene comprising a polynucleotide from SEQ.ID.N.3 that is co-expressed with one or more known kidney disease-associated genes in a plurality of biological samples, the corresponding purified polypeptide (SEQ.ID.N.10), an expression vector, a host cell, a pharmaceutical composition, an antibody or antibody fragment, and immunoconjugate; a method for diagnosing the disease associated with such gene and a method of treatment for such disease.

4. Claims: 2, 4-7,9-12,14-16 all partially and 1,3, 8 and 13 completely

A substantially purified polynucleotide comprising a gene comprising a polynucleotide from SEQ.ID.N.4 that is co-expressed with one or more known kidney

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

disease-associated genes in a plurality of biological samples, the corresponding purified polypeptide, an expression vector, a host cell, a pharmaceutical composition, an antibody or antibody fragment, and immunoconjugate; a method for diagnosing the disease associated with such gene and a method of treatment for such disease.

5. Claims: 2, 4-7,9-12,14-16 all partially and 1,3, 8 and 13 completely

A substantially purified polynucleotide comprising a gene comprising a polynucleotide from SEQ.ID.N.5 that is co-expressed with one or more known kidney disease-associated genes in a plurality of biological samples, the corresponding purified polypeptide (SEQ.ID.N.11), an expression vector, a host cell, a pharmaceutical composition, an antibody or antibody fragment, and immunoconjugate; a method for diagnosing the disease associated with such gene and a method of treatment for such disease.

6. Claims: 2, 4-7,9-12,14-16 all partially and 1,3, 8 and 13 completely

A substantially purified polynucleotide comprising a gene comprising a polynucleotide from SEQ.ID.N.6 that is co-expressed with one or more known kidney disease-associated genes in a plurality of biological samples, the corresponding purified polypeptide, an expression vector, a host cell, a pharmaceutical composition, an antibody or antibody fragment, and immunoconjugate; a method for diagnosing the disease associated with such gene and a method of treatment for such disease.

7. Claims: 2, 4-7,9-12,14-16 all partially and 1,3, 8 and 13 completely

A substantially purified polynucleotide comprising a gene comprising a polynucleotide from SEQ.ID.N.7 that is co-expressed with one or more known kidney disease-associated genes in a plurality of biological samples, the corresponding purified polypeptide (SEQ.ID.N.12), an expression vector, a host cell, a pharmaceutical composition, an antibody or antibody fragment, and immunoconjugate; a method for diagnosing the disease associated with such gene and a method of treatment for such disease.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

8. Claims: 2, 4-7,9-12,14-16 all partially and 1,3,
8 and 13 completely

A substantially purified polynucleotide comprising a gene comprising a polynucleotide from SEQ.ID.N.8 that is co-expressed with one or more known kidney disease-associated genes in a plurality of biological samples, the corresponding purified polypeptide, an expression vector, a host cell, a pharmaceutical composition, an antibody or antibody fragment, and immunoconjugate; a method for diagnosing the disease associated with such gene and a method of treatment for such disease.

9. Claims: 2, 4-7,9-12,14-16 all partially and 1,3,
8 and 13 completely

A substantially purified polynucleotide comprising a gene comprising a polynucleotide from SEQ.ID.N.9 that is co-expressed with one or more known kidney disease-associated genes in a plurality of biological samples, the corresponding purified polypeptide, an expression vector, a host cell, a pharmaceutical composition, an antibody or antibody fragment, and immunoconjugate; a method for diagnosing the disease associated with such gene and a method of treatment for such disease.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/08260

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9906439 A	11-02-1999	AU 8555298 A EP 0994899 A	22-02-1999 26-04-2000
